Current communication practices for biomarker testing in non-small cell lung cancer: Exploring patient and clinician perspectives

被引:2
|
作者
Pack, Allison [1 ,2 ,7 ]
Russell, Andrea [1 ,2 ]
Kircher, Sheetal [1 ,2 ]
Weldon, Christine [1 ,2 ,3 ,4 ]
Bailey, Stacy C. [1 ,2 ]
Lockwood, Karen [5 ]
Marquart, Tyler [5 ]
Afonso, Ana Sofia [6 ]
Payakachat, Nalin [5 ]
Wolf, Michael [1 ,2 ]
机构
[1] Northwestern Univ, Ctr Appl Hlth Res Aging, Feinberg Sch Med, Chicago, IL USA
[2] Northwestern Univ, Div Gen Internal Med, Feinberg Sch Med, Chicago, IL USA
[3] Northwestern Univ, Div Obstet & Gynecol, Feinberg Sch Med, Chicago, IL USA
[4] Ctr Business Models Healthcare, Glencoe, IL USA
[5] Eli Lilly & Co, Indianapolis, IN USA
[6] Eli Lilly BV, Utrecht, Netherlands
[7] Northwestern Univ, Div Gen Internal Med, Feinberg Sch Med, 750 N Lake Shore Dr, 10th Floor, Chicago, IL 60611 USA
基金
美国国家卫生研究院;
关键词
Non -small cell lung cancer; Patient education; Biomarker testing; LITERACY;
D O I
10.1016/j.pec.2023.107839
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives: We qualitatively explored patient and clinician experiences with biomarker testing in one academic health system to identify current communication practices and unmet testing information needs. Methods: We conducted 1:1 in-depth interviews with 15 clinicians (i.e., nurses, oncologists, pathologists) and 12 patients diagnosed with non-small cell lung cancer between January and May 2022. Participants described experiences with biomarker testing as well as associated communication practices and needs. Interviews were audio-recorded and transcribed. Analysis was informed by the Framework Method. Results: Patients described challenges retaining information early in their patient journey. While patients were generally aware of biomarkers and their effect on treatment options, they expressed limited knowledge of expected time delays between testing and receiving results. Additionally, many did not know their testing results. Clinicians and patients both noted no standard education material on biomarker testing is currently available. They suggested such materials could support patient knowledge and decision-making. Conclusions: Communication between patients and clinicians about biomarker testing is largely delivered through verbal counseling at a time when patients may be cognitively compromised. All participants supported the idea of delivering standard, tangible education materials on biomarker testing to patients. Practice implications: Education materials may enhance counseling efforts and patient knowledge.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Biomarker Testing in Non-Small Cell Lung Cancer A Clinician's Perspective
    Bernicker, Eric
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2015, 139 (04) : 448 - 450
  • [2] Biomarker Testing Practices for Non-small Cell Lung Cancer: A Survey of Veterans Affairs Facilities
    Vlachos, E. M.
    Dellitalia, J.
    Rubinstein, I.
    Maurice, N. M.
    Flores, N.
    Tanner, N. T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [3] Biomarker-Targeted Therapies in Non-Small Cell Lung Cancer: Current Status and Perspectives
    Guo, Haiyang
    Zhang, Jun
    Qin, Chao
    Yan, Hang
    Liu, Tao
    Hu, Haiyang
    Tang, Shengjie
    Tang, Shoujun
    Zhou, Haining
    CELLS, 2022, 11 (20)
  • [4] Current perspectives of KRAS in non-small cell lung cancer
    Harris, Ethan
    Thawani, Rajat
    CURRENT PROBLEMS IN CANCER, 2024, 51
  • [5] Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer
    Garon, Edward B.
    SEMINARS IN ONCOLOGY, 2015, 42 (05) : S11 - S18
  • [7] Current and future trends in non-small cell lung cancer biomarker testing: The American experience
    VanderLaan, Paul A.
    Roy-Chowdhuri, Sinchita
    CANCER CYTOPATHOLOGY, 2020, 128 (09) : 629 - 636
  • [8] Current Biomarker Testing Practices for Early Stage Non-small Cell Lung Cancer (NSCLC) In Community and Academic Centers in the US
    Smeltzer, M.
    Vimolratana, M.
    Shiller, M.
    Cattaneo, S. M.
    Gray, J.
    Stiles, B.
    Aversano, J.
    Lile, A.
    Plotkin, E.
    Kim, J.
    Boehmer, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S554 - S554
  • [9] Non-Small Cell Lung Cancer: Recommendations for Biomarker Testing and Treatment
    Aisner, Dara L.
    Riely, Gregory J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 610 - 613
  • [10] Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives
    Imyanitov, Evgeny N.
    Iyevleva, Aglaya G.
    Levchenko, Evgeny V.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 157